Home > Cardiology > Prasugrel superior to ticagrelor in reducing ischaemic events in ACS + planned invasive strategy

Prasugrel superior to ticagrelor in reducing ischaemic events in ACS + planned invasive strategy

Expert
Prof. Stefanie Schüpke, German Heart Centre Munich, Germany
Conference
ESC 2019
Trial
ISAR‑REACT 5
Acute coronary syndrome (ACS) patients with or without ST-segment elevation who received treatment with prasugrel had significantly reduced rates of the composite endpoint of death, myocardial infarction, or stroke without an increase in major bleeding compared with ticagrelor treatment. These results from the ISAR-REACT 5 study were presented during a Hot Line Session on Sunday 1 Sept at ESC Congress 2019. The ISAR‑REACT 5 trial is unique as it consisted of a head-to-head comparison of a ticagrelor vs prasugrel-based strategy in ACS patients with and without ST-segment elevation in terms of 1-year clinical outcomes [1]. “This was never done before; both drugs had only been compared with clopidogrel in ACS,” said Prof. Stefanie Schüpke (German Heart Centre Munich, Germany). The hypothesis of the trial was that ticagrelor would be superior to prasugrel in reducing the primary composite endpoint of death, myocardial infarction, or stroke within 12 months in ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on